Ved 24 måneder blev der observeret en signifikant øgning på 3, 6% i BMD over hele hoften hos patienter, som blev behandlet med Aclasta, svarende til effekten observeret hos post - menopausale kvinder i HORIZON- PFT studiet.
At 24 months a similar significant increase of 3.6% in total hip BMD was observed for patients treated with Aclasta as compared to the effects observed in post-menopausal women in the HORIZON-PFT study.